Home
Products
Colloidal Gold Platform
Drug Of Abuse
Gastrointestinal Diseases
Sexually Transmitted Disease
Respiratory Disease
Tropical Disease
Women Health
Hepatitis Disease
Cardiac Maker
Others
Fluorescence Platform
Fluorescence Immunoassay Analyzer
Fluorescence Immunoassay Tests
Veterinary Platform
Veterinary Fluorescence Immunoassay Analyzer
Veterinary Fluorescence Immunoassay Tests
Molecular Platform
Extraction Equipment
Extraction Kit
About us
Honor
The Core Team
News
Company news
Industry news
Contact
en
English
Español
Français
Deutsch
عربى
Web Menu
Home
Products
Colloidal Gold Platform
Drug Of Abuse
Gastrointestinal Diseases
Sexually Transmitted Disease
Respiratory Disease
Tropical Disease
Women Health
Hepatitis Disease
Cardiac Maker
Others
Fluorescence Platform
Fluorescence Immunoassay Analyzer
Fluorescence Immunoassay Tests
Veterinary Platform
Veterinary Fluorescence Immunoassay Analyzer
Veterinary Fluorescence Immunoassay Tests
Molecular Platform
Extraction Equipment
Extraction Kit
About us
Honor
The Core Team
News
Company news
Industry news
Contact
Product Search
Language
عربى
Español
English
Español
Français
Deutsch
عربى
Share
Exit Menu
News
Home
/
News
2022-07-01
Zhejiang Wantaifu Biotechnology Co., Ltd. has set sail!
In the morning of June 29th, Hangzhou IC Industrial Park held a grand signing ceremony of double-invitation projects. Xiaoshan District Committee, Xiaoshan Economic and Technological Development Zone and other relevant leaders attended the signing ce...
VIEW MORE
02
2025-Apr
What are the regulatory requirements, such as WHO prequalification, FDA clearance, or CE marking
The regulatory requirements for a Tuberculosis (TB) Antibody Rapid Test Device vary based on regional and international regulatory bodies. Key approvals and certifications include WHO prequalification, FDA clearance, and CE marking, each with specifi...
24
2025-Mar
Tuberculosis Antibody Rapid Test Devices: Technological Advances, Diagnostic Challenges, and Public Health Implications
Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, with an estimated 10.6 million cases and 1.3 million deaths reported globally in 2022 (WHO). In the fight against TB, rapid and accurate diagnostics are critical to curbing t...
21
2025-Mar
How can the results of Trichomonas vaginalis rapid tests be used to inform treatment decisions
The results of Trichomonas vaginalis rapid tests can play a crucial role in informing treatment decisions by providing timely and accurate diagnoses that guide clinicians in prescribing the appropriate therapy. Here's how these results can be effecti...
14
2025-Mar
What Are the Key Considerations for Developing and Implementing an Effective Gonorrhea Rapid Test?
Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is one of the most common sexually transmitted infections (STIs) globally. Its prevalence, coupled with the potential for severe complications such as pelvic inflammatory disease, infertility,...
04
2025-Mar
How Can Fluorescence Immunoassay Analyzers Transform Point-of-Care Testing?
Point-of-care testing (POCT) is revolutionizing the way healthcare providers diagnose and manage diseases. Fluorescence immunoassay analyzers, with their rapid, accurate, and cost-effective diagnostic capabilities, are playing a significant role in t...
25
2025-Feb
Is the Fluorescence Immunoassay Analyzer the Future of Diagnostic Precision?
The Fluorescence Immunoassay Analyzer represents a revolutionary approach to diagnostics, combining the power of fluorescence detection with immunoassay technology. By utilizing fluorescent labels and high-precision sensors, these analyzers can detec...
1
2
3
4
5
6
›
››
Submit feedback
Name:
*
Email:
Phone:
*
Message: